{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:10:57Z","timestamp":1784005857786,"version":"3.55.0"},"reference-count":39,"publisher":"Walter de Gruyter GmbH","issue":"8","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Endo Pharmaceuticals Inc","award":["Editorial\/medical writing assistance funding"],"award-info":[{"award-number":["Editorial\/medical writing assistance funding"]}]},{"name":"Endo Pharmaceuticals Inc","award":["Funding for programming support of stat analysis"],"award-info":[{"award-number":["Funding for programming support of stat analysis"]}]},{"name":"Endo Pharmaceuticals Inc","award":["Study funding"],"award-info":[{"award-number":["Study funding"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2020-0721_abs_001_w2aab3b7c27b1b6b1aab1c15b1Aa\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Gonadotropin-releasing hormone analogs are the treatment of choice for central precocious puberty (CPP). This study characterizes patients treated with histrelin implant or leuprolide injection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0721_abs_002_w2aab3b7c27b1b6b1aab1c15b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A US claims database was used to identify patients aged \u226420 years with \u22651 histrelin or leuprolide claim (index treatment) between April 2010 and November 2017 and continuous enrollment \u22653 months before and \u226512 months after the index treatment date.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0721_abs_003_w2aab3b7c27b1b6b1aab1c15b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 4,217 patients (histrelin, n=1,001; leuprolide, n=3,216) were identified. The percentage of patients with CPP diagnosis was greater in the histrelin (96.5%) vs. leuprolide (68.8%; p&lt;0.0001) cohort. In patients with CPP (histrelin, n=966; leuprolide, n=2,214), mean age at treatment initiation was similar for histrelin (9.0\u00a0\u00b1\u00a02.0 years) and leuprolide (9.1\u00a0\u00b1\u00a02.3 years), with &gt;50% of patients aged 6\u20139 years. Mean treatment duration was significantly longer for histrelin (26.7\u00a0\u00b1\u00a014.8 months) vs. leuprolide (14.1\u00a0\u00b1\u00a012.1 months; p&lt;0.0001), and was longer in younger patient groups. More patients switched from leuprolide to histrelin (12.3%) than vice versa (3.6%; p&lt;0.0001). Median annual total treatment costs were slightly lower for the histrelin cohort ($23,071 [interquartile range, $16,833\u2013$31,050]) than the leuprolide cohort ($27,021 [interquartile range, $18,314\u2013$34,995]; p&lt;0.0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0721_abs_004_w2aab3b7c27b1b6b1aab1c15b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with CPP treated with histrelin had a longer duration of treatment, lower rates of index treatment discontinuation, and lower annual treatment costs vs. those treated with leuprolide.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2020-0721","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T22:06:48Z","timestamp":1624140408000},"page":"961-969","source":"Crossref","is-referenced-by-count":3,"title":["Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database"],"prefix":"10.1515","volume":"34","author":[{"given":"Lawrence A.","family":"Silverman","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology , Goryeb Children\u2019s Hospital Atlantic Health , Morristown , NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Han","sequence":"additional","affiliation":[{"name":"IQVIA , Durham , NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Huang","sequence":"additional","affiliation":[{"name":"IQVIA , Durham , NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee M.","family":"Near","sequence":"additional","affiliation":[{"name":"IQVIA , Durham , NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Hu","sequence":"additional","affiliation":[{"name":"Endo Pharmaceuticals Inc. , Malvern , PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"2023040101170326956_j_jpem-2020-0721_ref_001_w2aab3b7c27b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Carel, JC, L\u00e9ger, J. Precocious puberty. N Engl J Med 2008;358:2366\u201377. https:\/\/doi.org\/10.1056\/nejmcp0800459.","DOI":"10.1056\/NEJMcp0800459"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_002_w2aab3b7c27b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Nebesio, TD, Eugster, EA. Current concepts in normal and abnormal puberty. Curr Probl Pediatr Adolesc Health Care 2007;37:50\u201372. https:\/\/doi.org\/10.1016\/j.cppeds.2006.10.005.","DOI":"10.1016\/j.cppeds.2006.10.005"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_003_w2aab3b7c27b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Partsch, CJ, Sippell, WG. Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens. Hum Reprod Update 2001;7:292\u2013302. https:\/\/doi.org\/10.1093\/humupd\/7.3.292.","DOI":"10.1093\/humupd\/7.3.292"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_004_w2aab3b7c27b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Soriano-Guill\u00e9n, L, Corripio, R, Labarta, JI, Canete, R, Castro-Feijoo, L, Espino, R, et al.. Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab 2010;95:4305\u201313. https:\/\/doi.org\/10.1210\/jc.2010-1025.","DOI":"10.1210\/jc.2010-1025"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_005_w2aab3b7c27b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Carel, JC, Lahlou, N, Roger, M, Chaussain, JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135\u201347. https:\/\/doi.org\/10.1093\/humupd\/dmh012.","DOI":"10.1093\/humupd\/dmh012"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_006_w2aab3b7c27b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Stice, E, Presnell, K, Bearman, SK. Relation of early menarche to depression, eating disorders, substance abuse, and comorbid psychopathology among adolescent girls. Dev Psychol 2001;37:608\u201319. https:\/\/doi.org\/10.1037\/0012-1649.37.5.608.","DOI":"10.1037\/0012-1649.37.5.608"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_007_w2aab3b7c27b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Mendle, J, Ryan, RM, McKone, KMP. Age at menarche, depression, and antisocial behavior in adulthood. Pediatrics 2018;141:e20171703. https:\/\/doi.org\/10.1542\/peds.2017-1703.","DOI":"10.1542\/peds.2017-1703"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_008_w2aab3b7c27b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Reardon, LE, Leen-Feldner, EW, Hayward, C. A critical review of the empirical literature on the relation between anxiety and puberty. Clin Psychol Rev 2009;29:1\u201323. https:\/\/doi.org\/10.1016\/j.cpr.2008.09.005.","DOI":"10.1016\/j.cpr.2008.09.005"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_009_w2aab3b7c27b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Latronico, AC, Brito, VN, Carel, J-C. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol 2016;4:265\u201374. https:\/\/doi.org\/10.1016\/s2213-8587(15)00380-0.","DOI":"10.1016\/S2213-8587(15)00380-0"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_010_w2aab3b7c27b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Carel, JC, Eugster, EA, Rogol, A, Ghizzoni, L, Palmert, MR, ESPE-LWPES GnRH Analogs Consensus Conference Group, et al.. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752\u201362. https:\/\/doi.org\/10.1542\/peds.2008-1783.","DOI":"10.1542\/peds.2008-1783"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_011_w2aab3b7c27b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Kaplowitz, P, Bloch, C. Section on Endocrinology of the American Academy of Pediatrics. Evaluation and referral of children with signs of early puberty. Pediatrics 2016;137:e20153732. https:\/\/doi.org\/10.1542\/peds.2015-3732.","DOI":"10.1542\/peds.2015-3732"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_012_w2aab3b7c27b1b6b1ab2b2c12Aa","unstructured":"Supprelin LA (histrelin acetate) subcutaneous implant. Malvern, PA: Endo Pharmaceuticals Inc; 2019."},{"key":"2023040101170326956_j_jpem-2020-0721_ref_013_w2aab3b7c27b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Eugster, EA, Clarke, W, Kletter, GB, Lee, PA, Neely, EK, Reiter, EO, et al.. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007;92:1697\u2013704. https:\/\/doi.org\/10.1210\/jc.2006-2479.","DOI":"10.1210\/jc.2006-2479"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_014_w2aab3b7c27b1b6b1ab2b2c14Aa","unstructured":"Lupron Depot-PED (leuprolide acetate for depot suspension) injection, powder, lyophilized, for suspension. North Chicago, IL: AbbVie Inc.; 2020."},{"key":"2023040101170326956_j_jpem-2020-0721_ref_015_w2aab3b7c27b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Carel, JC, Lahlou, N, Jaramillo, O, Montauban, V, Teinturier, C, Colle, M, et al.. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111\u20136. https:\/\/doi.org\/10.1210\/jc.2001-020243.","DOI":"10.1210\/jc.2001-020243"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_016_w2aab3b7c27b1b6b1ab2b2c16Aa","unstructured":"Triptodur (triptorelin) for extended-release injectable suspension, for intramuscular use. Atlanta, GA: Arbor Pharmaceuticals, LLC; 2018."},{"key":"2023040101170326956_j_jpem-2020-0721_ref_017_w2aab3b7c27b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Klein, K, Yang, J, Aisenberg, J, Wright, N, Kaplowitz, P, Lahlou, N, et al.. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab 2016;29:1241\u20138. https:\/\/doi.org\/10.1515\/jpem-2015-0376.","DOI":"10.1515\/jpem-2015-0376"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_018_w2aab3b7c27b1b6b1ab2b2c18Aa","unstructured":"Fensolvi (leuprolide acetate) for injectable suspension, for subcutaneous use. Fort Collins, CO: Tolmar Pharmaceuticals, Inc.; 2020."},{"key":"2023040101170326956_j_jpem-2020-0721_ref_019_w2aab3b7c27b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Klein, KO, Freire, A, Gryngarten, MG, Kletter, GB, Benson, M, Miller, BS, et al.. Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty. J Clin Endocrinol Metab 2020;105:1\u201312. https:\/\/doi.org\/10.1210\/clinem\/dgaa479.","DOI":"10.1210\/clinem\/dgaa479"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_020_w2aab3b7c27b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Rahhal, S, Clarke, WL, Kletter, GB, Lee, PA, Neely, EK, Reiter, EO, et al.. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009;2009:812517. https:\/\/doi.org\/10.1186\/1687-9856-2009-812517.","DOI":"10.1186\/1687-9856-2009-812517"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_021_w2aab3b7c27b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Neely, EK, Lee, PA, Bloch, CA, Larsen, L, Yang, D, Mattia-Goldberg, C, et al.. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010;2010:398639. https:\/\/doi.org\/10.1186\/1687-9856-2010-398639.","DOI":"10.1186\/1687-9856-2010-398639"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_022_w2aab3b7c27b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Gillis, D, Karavani, G, Hirsch, HJ, Strich, D. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr 2013;163:532\u20136. https:\/\/doi.org\/10.1016\/j.jpeds.2013.01.021.","DOI":"10.1016\/j.jpeds.2013.01.021"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_023_w2aab3b7c27b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Fisher, MM, Lemay, D, Eugster, EA. Resumption of puberty in girls and boys following removal of the histrelin implant. J Pediatr 2014;164:912\u20136 e1. https:\/\/doi.org\/10.1016\/j.jpeds.2013.12.009.","DOI":"10.1016\/j.jpeds.2013.12.009"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_024_w2aab3b7c27b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Silverman, LA, Neely, EK, Kletter, GB, Lewis, K, Chitra, S, Terleckyj, O, et al.. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial. J Clin Endocrinol Metab 2015;100:2354\u201363. https:\/\/doi.org\/10.1210\/jc.2014-3031.","DOI":"10.1210\/jc.2014-3031"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_025_w2aab3b7c27b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Heger, S, M\u00fcller, M, Ranke, M, Schwarz, HP, Waldhauser, F, Partsch, CJ, et al.. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006;254\u2013255:217\u201320. https:\/\/doi.org\/10.1016\/j.mce.2006.04.012.","DOI":"10.1016\/j.mce.2006.04.012"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_026_w2aab3b7c27b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Lazar, L, Meyerovitch, J, de Vries, L, Phillip, M, Lebenthal, Y. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol (Oxf) 2014;80:570\u20136. https:\/\/doi.org\/10.1111\/cen.12319.","DOI":"10.1111\/cen.12319"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_027_w2aab3b7c27b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Lazar, L, Lebenthal, Y, Yackobovitch-Gavan, M, Shalitin, S, de Vries, L, Phillip, M, et al.. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades. J Clin Endocrinol Metab 2015;100:1445\u201351. https:\/\/doi.org\/10.1210\/jc.2014-3748.","DOI":"10.1210\/jc.2014-3748"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_028_w2aab3b7c27b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Guaraldi, F, Beccuti, G, Gori, D, Ghizzoni, L. Management of endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol 2016;174:R79\u201387. https:\/\/doi.org\/10.1530\/eje-15-0590.","DOI":"10.1530\/EJE-15-0590"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_029_w2aab3b7c27b1b6b1ab2b2c29Aa","unstructured":"Thornton, P, Silverman, LA, Geffner, ME, Neely, EK, Gould, E, Danoff, TM. Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty. Pediatr Endocrinol Rev 2014;11:306\u201317."},{"key":"2023040101170326956_j_jpem-2020-0721_ref_030_w2aab3b7c27b1b6b1ab2b2c30Aa","unstructured":"Zubeldia, K, Romney, GW. Anonymously linking a plurality of data records. US patent US6397224B1, 2002. https:\/\/patents.google.com\/patent\/US6397224B1\/en [Accessed 8 Feb 2021]."},{"key":"2023040101170326956_j_jpem-2020-0721_ref_031_w2aab3b7c27b1b6b1ab2b2c31Aa","unstructured":"Ober, NS, Grubmuller, J, Farrell, M, Wentworth, C, Gilbert, T, Barrett, K, et al.. System and method for generating de-identified health care data. US patent US7376677B2, 2008. https:\/\/patents.google.com\/patent\/US7376677B2\/en?oq=US7376677B2 [Accessed 8 Feb 2021]."},{"key":"2023040101170326956_j_jpem-2020-0721_ref_032_w2aab3b7c27b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Lopez, CM, Solomon, D, Boulware, SD, Christison-Lagay, E. Trends in the \u201coff-label\u201d use of GnRH agonists among pediatric patients in the United States. Clin Pediatr (Phila) 2018;57:1432\u20135. https:\/\/doi.org\/10.1177\/0009922818787260.","DOI":"10.1177\/0009922818787260"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_033_w2aab3b7c27b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Lopez, CM, Solomon, D, Boulware, SD, Christison-Lagay, ER. Trends in the use of puberty blockers among transgender children in the United States. J Pediatr Endocrinol Metab 2018;31:665\u201370. https:\/\/doi.org\/10.1515\/jpem-2018-0048.","DOI":"10.1515\/jpem-2018-0048"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_034_w2aab3b7c27b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Klein, KO, Barnes, KM, Jones, JV, Feuillan, PP, CutlerJr.GB. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711\u20136. https:\/\/doi.org\/10.1210\/jcem.86.10.7915.","DOI":"10.1210\/jcem.86.10.7915"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_035_w2aab3b7c27b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Eugster, EA. Treatment of central precocious puberty. J Endocr Soc 2019;3:965\u201372. https:\/\/doi.org\/10.1210\/js.2019-00036.","DOI":"10.1210\/js.2019-00036"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_036_w2aab3b7c27b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Kaplowitz, PB, Backeljauw, PF, Allen, DB. Toward more targeted and cost-effective gonadotropin-releasing hormone analog treatment in girls with central precocious puberty. Horm Res Paediatr 2018;90:1\u20137. https:\/\/doi.org\/10.1159\/000491103.","DOI":"10.1159\/000491103"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_037_w2aab3b7c27b1b6b1ab2b2c37Aa","doi-asserted-by":"crossref","unstructured":"Lewis, KA, Goldyn, AK, West, KW, Eugster, EA. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Pediatr 2013;163:1214\u20136. https:\/\/doi.org\/10.1016\/j.jpeds.2013.05.033.","DOI":"10.1016\/j.jpeds.2013.05.033"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_038_w2aab3b7c27b1b6b1ab2b2c38Aa","doi-asserted-by":"crossref","unstructured":"Swendiman, RA, Vogiatzi, MG, Alter, CA, Nance, ML. Histrelin implantation in the pediatric population: a 10-year institutional experience. J Pediatr Surg 2019;54:1457\u201361. https:\/\/doi.org\/10.1016\/j.jpedsurg.2018.08.048.","DOI":"10.1016\/j.jpedsurg.2018.08.048"},{"key":"2023040101170326956_j_jpem-2020-0721_ref_039_w2aab3b7c27b1b6b1ab2b2c39Aa","doi-asserted-by":"crossref","unstructured":"Klein, KO, Soliman, AM, Bonafede, M, Nelson, JK, Grubb, E. Treatment patterns, health resource utilization and costs among central precocious puberty patients treated with leuprolide or histrelin: an examination of the commercial and Medicaid populations. J Med Econ 2020;23:407\u201314. https:\/\/doi.org\/10.1080\/13696998.2019.1697700.","DOI":"10.1080\/13696998.2019.1697700"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0721\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T19:12:01Z","timestamp":1680376321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0721\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,6,14]]},"published-print":{"date-parts":[[2021,8,26]]}},"alternative-id":["10.1515\/jpem-2020-0721"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2020-0721","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}